Navigation Links
Structure of TB Enzyme Points the Way to New Drugs: Study

Swiss scientists said Monday that they have further evidence to suggest that an enzyme secreted by the microbe that causes tuberculosis would make a promising target for new drugs to combat the deadly infectious disease.

The Swiss team first identified the enzyme, protein kinase G (PknG), as a promising drug target back in 2004.

At the time, they said that the protein is the secret weapon that enables the TB bug, Mycobacterium tuberculosis, to avoid being hunted down and destroyed by the body's immune system sentinels as most other pathogens are.

The protein apparently interferes with the functioning of the cells called macrophages that typically engulf and digest pathogens. Instead of absorbing and destroying the TB bacteria, the macrophages become host cells where the germ hides out.

In the same paper, the investigators said they had also identified a compound that could block the suspect protein, but they were concerned that by inhibiting this one protein, they would interfere with the action of other similar proteins secreted by the host cell.

"We wanted to be sure that inhibitors of mycobacterial PknG would not interefere with important host cellular functions," said Jean Pieters, a professor of biochemistry at the University of Basle in Switzerland and lead author of the paper.

So Pieters and colleagues decided to examine the chemical structure of the PknG molecule and the compound that inhibits it in atomic resolution, using a technique called X-ray crystallography.

They found that the compound acted on a segment of the protein that is unique to PknG -- not shared by any of the other 491 protein kinases that have been identified and sequenced thanks to the mapping of the human genome.

"Since we now know exactly what the requirements should be for a good blocker and how to avoid interference with host kinases, we should now be able to rationally des ign compounds that are highly effective against PknG," said Pieters.

Tuberculosis kills millions of people every year, and many millions more carry the bug in a latent form.

Antibiotics that are used to treat the illness are decades old, can be toxic and don't work on the bacteria in its dormant stage. What's more, some virulent strains of the airborne germ have emerged that are extensively drug resistant.

Pieters said that the new drugs by targeting different pathways than those used by existing antibiotics should side-step various problems with these drugs, specifically their inability to destroy the bacteria in its dormant form, which is one of the reasons that resistance has emerged.

The study appears in the Proceedings of the National Academy of Sciences.


'"/>




Related medicine news :

1. Relationship Between Genetic Structure And Quality of Life
2. Abnormal Brain Structure One Of The Reasons For Depression in Adolescents
3. Structure of the brain to increase risk for anxiety disorders
4. Changes In Brain Structure From Methamphetamine Abuse And HIV Infection
5. Almond Structure in the Brain Intrigues Researchers
6. Controversy over Fees Structure in Private Medical Colleges
7. Controversy Over The Fee Structure In Private Medical Colleges Surfaces Yet Again
8. Education Structure In Indian Schools To Be Revamped Soon
9. Neither Management Nor Students Happy With New Fee Structure
10. DNA-bound p53 Tumor Suppressor Protein Structure Determined
11. Structure of DNA-modifying enzyme In Small Pox Determined
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe ... from the David Geffen School of Medicine at UCLA. He trained in Internal Medicine ... his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article ... are unfamiliar with. The article goes on to state that individuals are now more ... these less common operations such as calf and cheek reduction. The Los Angeles area ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary Hypertension ... that it will receive two significant new grants to support its work to ... its 25th anniversary by recognizing patients, medical professionals and scientists for their work ...
(Date:6/24/2016)... ... ... of Topricin and MyPainAway Pain Relief Products, join The ‘Business for a Fair Minimum Wage’ ... 2020 and then adjusting it yearly to increase at the same rate as the median ... floor does not erode again, and make future increases more predictable. , The company is ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... Investment Group (TGIG), has initiated cultivation and processing operations at its production facility, ... Pahrump, Nevada. , Puradigm is the manufacturer of a complete system of proactive ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... Research and Markets has announced ... Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), Functionality ... - Global Forecast to 2021" report to their ... global pharmaceutical excipients market is projected to reach USD ... in the forecast period 2016 to 2021. ...
(Date:6/23/2016)... Research and Markets has announced the addition of the ... to 2022" report to their offering. ... financial data derived from varied research sources to present unique ... on the market during the next five years, including a ... markets, regional and country level analysis. The report provides a ...
(Date:6/23/2016)... 23, 2016 Bracket , a leading clinical ... generation clinical outcomes platform, Bracket eCOA (SM) 6.0, at ... 26 – 30, 2016 in Philadelphia , ... Outcome Assessment product of its kind to fully integrate with ... Bracket eCOA 6.0 is a flexible platform for electronic clinical ...
Breaking Medicine Technology: